Clinical Significance of Platelet Count at day +60 After Allogeneic Peripheral Blood Stem Cell Transplantation.
10.3346/jkms.2006.21.1.46
- Author:
Dong Hwan KIM
1
;
Sang Kyun SOHN
;
Jin Ho BAEK
;
Jong Gwang KIM
;
Nan Young LEE
;
Dong Il WON
;
Jang Soo SUH
;
Kyu Bo LEE
Author Information
1. Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea. sksohn@knu.ac.kr
- Publication Type:Original Article
- Keywords:
Thrombocytopenia;
Transplantation, Homologous;
Allogeneic;
Peripheral Blood Stem Cell Transplantation;
Mortality;
Opportunistic Infections
- MeSH:
Adolescent;
Adult;
Antigens, CD34/blood;
Female;
Hematologic Diseases/blood/surgery;
Humans;
Male;
Middle Aged;
Multivariate Analysis;
Neoplasms/blood/surgery;
*Peripheral Blood Stem Cell Transplantation;
Platelet Count;
Prognosis;
Survival Analysis;
Time Factors;
Transplantation, Homologous;
Treatment Outcome
- From:Journal of Korean Medical Science
2006;21(1):46-51
- CountryRepublic of Korea
- Language:English
-
Abstract:
Thrombocytopenia (TP) is a frequent complication after allogeneic stem cell transplantation (SCT) and regarded as a poor prognostic factor, especially in patients with chronic graft-versus-host disease (GVHD), although various factors were related to the development of TP after allogeneic SCT. Sixty-three patients receiving allogeneic peripheral blood stem cell transplantation (PBSCT) were stratified according to platelet count (PC) at day +60 and analyzed in terms of overall survival (OS) and the incidence of non-relapse mortality (NRM). Ten patients (15.9%) were stratified in group 1 (PC < or =29 x 10(9)/L), 23 patients (36.5%) in group 2 (PC 30-79 x 10(9)/L), and 30 patients in group 3 (PC > or =80 x 10(9)/L). Group 3 was associated with lower incidence of extensive chronic GVHD (p=0.013), better 3-yr OS (p=0.0030), and lower NRM rate (p<0.0001). In multivariate analyses, the PC at day +60 was identified as an independent prognostic factor (p=0.003) together with CD34+ cell dose (p<0.001), disease risk (p=0.004), and acute GVHD (p=0.033) in terms of NRM, and the PC (p=0.047) and CD34+ cell dose (p=0.026) in terms of incidence of infectious events. Measuring the platelet count at day +60 is a simple method for predicting the risk of chronic GVHD development and prognosis after allogeneic PBSCT.
